132 related articles for article (PubMed ID: 11747276)
1. Implications of occult metastatic cells for systemic cancer treatment in patients with breast or gastrointestinal cancer.
Braun S; Rosenberg R; Thorban S; Harbeck N
Semin Surg Oncol; 2001 Jun; 20(4):334-46. PubMed ID: 11747276
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of occult metastatic cells in bone marrow of breast cancer patients.
Braun S; Pantel K
Oncologist; 2001; 6(2):125-32. PubMed ID: 11306724
[TBL] [Abstract][Full Text] [Related]
3. Molecular markers of metastasis in breast cancer: current understanding and prospects for novel diagnosis and prevention.
Braun S; Harbeck N
Expert Rev Mol Med; 2001 Sep; 3(22):1-14. PubMed ID: 14585146
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in technologies for the detection of occult metastatic cells in bone marrow of breast cancer patients.
Braun S; Harbeck N
Breast Cancer Res; 2001; 3(5):285-8. PubMed ID: 11597315
[TBL] [Abstract][Full Text] [Related]
5. [Micrometastatic cells in the bone marrow of patients with breast carcinoma].
Diel IJ; Solomayer EF; Bastert G
Radiologe; 2000 Aug; 40(8):681-7. PubMed ID: 11006937
[TBL] [Abstract][Full Text] [Related]
6. [Importance of occult metastatic cells in the treatment of patients with breast and gastrointestinal cancers].
Braun S; Auer M; Rosenberg R
Acta Med Austriaca Suppl; 2002; 59():18-26. PubMed ID: 12506756
[TBL] [Abstract][Full Text] [Related]
7. Molecular detection of disseminated breast cancer cells in the bone marrow of early breast cancer patients using quantitative RT PCR for CEA.
Janku F; Srovnal J; Korinkova G; Novotny J; Petruzelka L; Power D; Matous B; Hajduch M
Neoplasma; 2008; 55(4):317-22. PubMed ID: 18505343
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow micrometastases and gastrointestinal cancer detection and significance.
Maguire D; O'Sullivan GC; Collins JK; Morgan J; Shanahan F
Am J Gastroenterol; 2000 Jul; 95(7):1644-51. PubMed ID: 10925963
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of micrometastatic bone marrow involvement.
Braun S; Pantel K
Breast Cancer Res Treat; 1998; 52(1-3):201-16. PubMed ID: 10066083
[TBL] [Abstract][Full Text] [Related]
10. Micrometastatic bone marrow involvement: detection and prognostic significance.
Braun S; Pantel K
Med Oncol; 1999 Sep; 16(3):154-65. PubMed ID: 10523795
[TBL] [Abstract][Full Text] [Related]
11. Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: towards a novel surrogate test to monitor adjuvant therapies of solid tumours.
Schlimok G; Pantel K; Loibner H; Fackler-Schwalbe I; Riethmüller G
Eur J Cancer; 1995 Oct; 31A(11):1799-803. PubMed ID: 8541104
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of bone marrow micrometastases of breast tumors].
Dubecz S; Csuka O; Török K; Vasas N; Péley G; Doleschal Z; Sulyok Z; Láng I; Köves I
Magy Seb; 2003 Aug; 56(3-4):108-12. PubMed ID: 14619093
[TBL] [Abstract][Full Text] [Related]
13. [Minimal residual disease in breast carcinoma].
Janků F; Novotný J; Vedralová J; Kleibl Z; Matous B; Petruzelka L
Cas Lek Cesk; 2002 Aug; 141(17):546-50. PubMed ID: 12404958
[TBL] [Abstract][Full Text] [Related]
14. Expression of heterochromatin protein 1 in the primary tumor of breast cancer patients in the presence or absence of occult metastatic cells in the bone marrow.
Abreu AP; Milani C; Katayama ML; Barbosa KC; Gomes da Fonseca L; Goes JC; Brentani MM; Koike Folgueira MA
Int J Biol Markers; 2008; 23(4):219-24. PubMed ID: 19199269
[TBL] [Abstract][Full Text] [Related]
15. Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer.
Benoy IH; Salgado R; Elst H; Van Dam P; Weyler J; Van Marck E; Scharpé S; Vermeulen PB; Dirix LY
Breast Cancer Res; 2005; 7(2):R210-9. PubMed ID: 15743502
[TBL] [Abstract][Full Text] [Related]
16. [Detection of disseminated carcinoma cells in bone marrow and peripheral blood in primary breast cancer with RT/PCR of parathyroid hormone-related protein (PTHrP)].
Liersch T; Gatzemeier W; Scharnberg P; Jürgens B; Wörmann B; Becker H; Rauschecker HF; Hiddemann W; Wulf GG
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):277-80. PubMed ID: 14518259
[TBL] [Abstract][Full Text] [Related]
17. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.
Braun S; Pantel K; Müller P; Janni W; Hepp F; Kentenich CR; Gastroph S; Wischnik A; Dimpfl T; Kindermann G; Riethmüller G; Schlimok G
N Engl J Med; 2000 Feb; 342(8):525-33. PubMed ID: 10684910
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of disseminated tumor cells as detected by quantitative real-time reverse-transcriptase polymerase chain reaction in patients with breast cancer.
Benoy IH; Elst H; Philips M; Wuyts H; Van Dam P; Scharpé S; Van Marck E; Vermeulen PB; Dirix LY
Clin Breast Cancer; 2006 Jun; 7(2):146-52. PubMed ID: 16800974
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of bladder cancer patients with disseminated tumour cells in bone marrow.
Retz M; Rotering J; Nawroth R; Buchner A; Stöckle M; Gschwend JE; Lehmann J
Eur Urol; 2011 Aug; 60(2):231-8. PubMed ID: 21190793
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer.
Diel IJ; Cote RJ
Cancer Treat Rev; 2000 Feb; 26(1):53-65. PubMed ID: 10660491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
